Fujian Haixi Pharma Gets Positive Data from Two Trials of Macular Degeneration Drug
MT Newswires Live
Yesterday
Fujian Haixi Pharmaceuticals (HKG:2637) obtained clinical data from the phase I and II clinical studies of HX9428 for the treatment of neovascular age-related macular degeneration.
In the phase I study, the drug demonstrated an improving trend in visual function and macular anatomical parameters.
Overall tole ratability was favorable and no dose-limiting toxicity was observed at any dose level.
In the ongoing phase II dose expansion trial, the overall efficacy trend was consistent with the results of the phase I study, with favorable overall tolerability.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.